Erlotinib: optimizing therapy with predictors of response?

Clin Cancer Res. 2006 May 15;12(10):2961-3. doi: 10.1158/1078-0432.CCR-06-0426.
No abstract available

MeSH terms

  • Biomarkers
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Clinical Trials as Topic
  • DNA Mutational Analysis
  • Drug Resistance, Neoplasm
  • Endpoint Determination
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Erlotinib Hydrochloride
  • Forecasting
  • Gene Amplification
  • Humans
  • Lung Neoplasms / drug therapy*
  • Prognosis
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / adverse effects
  • Quinazolines / therapeutic use*

Substances

  • Biomarkers
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors